This week, fast-food king-pin McDonald’s (NYSE:MCD) unveiled in Japan its newest creation- Mega Fries. The three-quarters of a pound, 1142 calorie serving of french fries- while potentially delicious- underscores that our new diet of convenience and excess is having some sobering effects on our heaths. As the world moves towards less physical activity and increased consumption of nutritionally deficient foods with higher levels of sugar and saturated fats, obesity rates and its complications will continue to rise, globally.
Incidences of one of those complications- diabetes- is rising at an exponential pace.
For investors, we can find opportunities in this sobering statistic in the companies that are working towards a cure or treat diabetes. 

A Growing Global Problem 
The National Institute of Health estimates that obesity and related complications such as diabetes are our nation's chief health concern. However, while most people tend to think of diabetes and obesity as a developed market problem, the two issues are spreading quite rapidly across the globe. Roughly, four out of five people suffering from diabetes are now located in developing markets. China alone, has 92.3 million diabetic citizens, while India’s diabetic population is over 50 million. Overall, there are nearly 371 million people across the globe that suffer from diabetes and plenty more that are in pre-diabetic stages.
However, there ranks are growing quite rapidly.
According to a new report from The International Diabetes Federation (IDF), at least one in 10 adults will have diabetes by 2030. Based on factors like aging, demographic changes, diet changes and increasing sedentary lifestyles, the group predicts that an estimated 552 million people could have diabetes in less than two decades' time. Overall, the IDF expects the number of cases to jump by 90% with the biggest contributor of new cases coming from the emerging world. This new report echoes similar statements made by the World Health Organization and Centers For Disease Control.  
All in all, the growing number of people who suffer from the disease will push the global spending for diabetes to reach $48 to $53 billion by 2016. That’s some serious spending amounts and could be lucrative opportunity for investors.
A Diabetes Portfolio 
Given just how big of an epidemic that diabetes has become, investors may want to contribute some capital to the sector. Many major pharmaceutical firms like Eli Lilly (NYSE:LLY) or Sanofi (NYSE: SNY) have divisions devoted to diabetes care and treatment. However, some of the best opportunities could be in the firms that specialize in the diseases care.
While there are several new therapy's in the works for diabetes care- such as MannKind’s (NASDAQ: MNKD) inhaled insulin drug Afrezza- injectable insulin still remains at the bread and butter of the industry. Novo Nordisk (NYSE:NVO) became one of the first manufacturers of insulin in 1923 and currently supplies more than half of the world’s dosage. The position is being strengthened in the emerging world as Novo has undergone a pricing strategy-in places like Africa and India- that helps get its insulin products into the hands of the poor for dirt cheap. Given the population sizes of these markets, Novo believes that over time volume of insulin sold will lead to serious profits. As such, investors may want to go with the leader in the space.
The diabetes sub-sector is the largest market for medical devices. Analysts estimate that in the U.S. alone will reach $20 billion by next year. Investors can play the device angle through several avenues from syringe manufacturers like Retractable Technologies (NYSE:RVP) and West Pharmaceutical (NYSE:WST), glucose monitors through Becton, Dickinson and Company (NYSE:BDX) or cutting edge insulin pumps through Insulet Corporation (NASDAQ: PODD).
Finally, one of the sad potential side-effects of diabetes is kidney failure and millions of people around the world suffer from this condition. DaVita (NYSE:DVA) owns and operate kidney dialysis centers with primarily focus on the United States. The company’s future potential hasn’t gone unnoticed as America’s favorite value investors- Warren Buffett- has taken a sizable stake in the firm. Incidentally, Buffett also holds a stake in Becton; Dickinson. Retail investors may want to follow suit as the epidemic continues to grow.
The Bottom Line
Sadly, diabetes is quickly becoming a global epidemic. As inactivity and high fat diets continue to seep into our lifestyles, the problems will compound themselves. Within these grim statistics, investors can find opportunities with the companies that are fighting this epidemic. The previous stocks represent a good starting point for further research.

Related Articles
  1. Stock Analysis

    Will J.C. Penney Come Back in 2016? (JCP)

    J.C. Penney is without a doubt turning itself around, but that doesn't guarantee the stock will respond immediately.
  2. Stock Analysis

    4 Reasons Gilead Sciences Should be in Your Stock Portfolio

    Discover how Gilead Sciences fits into most investment portfolios and learn about the company's drug pipeline and future growth catalysts.
  3. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  4. Stock Analysis

    How Is Walmart's Pharmacy Business Performing?

    Learn how Wal-Mart started its pharmacy business in 2006 and rose to be the fourth-largest U.S. drug store chain in 2014 but is struggling financially in 2015.
  5. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  6. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  7. Investing

    The Hazey Outlook for the Marijuana Industry

    Political change involving marijuana legalization lags behind the public's support for marijuana. It's a booming industry facing many challenges.
  8. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  9. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  10. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center